mRECIST & RECIST 1.1 Tumor Response Calculator
Accurately evaluate treatment response for Hepatocellular Carcinoma (HCC) and solid tumors. Computes percentage change in viable contrast-enhancing tumor burden, tracks up to 5 target lesions, and provides instant overall response classification (CR, PR, SD, PD).
Enter longest diameter of viable (arterially enhancing) tumor in millimeters (mm). Enter 0 if completely absent.
| # | Anatomical Location | Baseline Diameter (mm) | Follow-up Diameter (mm) | Status |
|---|---|---|---|---|
| 1 | Active | |||
| 2 | Active | |||
| 3 | Optional | |||
| 4 | Optional | |||
| 5 | Optional |
Achieved ≥ 30% decrease in the sum of viable tumor diameters without progression in non-target lesions or new lesions.
Understanding mRECIST vs. RECIST 1.1 Criteria in Oncology
In targeted and locoregional cancer therapies (such as Transarterial Chemoembolization [TACE], Yttrium-90 Radioembolization [SIRT], and tyrosine kinase inhibitors like Sorafenib / Lenvatinib), conventional RECIST 1.1 based solely on morphological lesion diameter often misclassifies tumor response. Effective anti-angiogenic and embolization therapies cause extensive central necrosis without immediate reduction in overall lesion size.
Key Differences: mRECIST for HCC vs. RECIST 1.1
- mRECIST for Hepatocellular Carcinoma (JNCI 2010): Measures only the contrast-enhancing viable portion of the tumor in the arterial phase of dynamic CT or contrast-enhanced MRI. Non-enhancing necrotic zones are excluded from measurement.
- RECIST 1.1 (Eur J Cancer 2009): Measures the longest unidimensional diameter of target lesions regardless of internal necrosis or cystic change.
Standardized Response Categories
- Complete Response (CR): Complete disappearance of all intratumoral arterial enhancement in all target lesions.
- Partial Response (PR): At least a 30% decrease in the sum of diameters of viable target lesions compared with baseline.
- Stable Disease (SD): Any disease response not qualifying as either PR (≥30% decrease) or PD (≥20% increase).
- Progressive Disease (PD): At least a 20% increase in the sum of diameters of viable target lesions taking as reference the smallest sum recorded since treatment started, OR the emergence of any new tumor lesion.
Clinical References
- Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52-60.
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
- European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236.